Table 1 |
||||
|
Comparison of the effect of ibandronate on six breast cancer cell lines |
||||
|
IC50 (μmol/l) |
||||
|
|
||||
|
Cell line |
ER statusa |
Bone lesionsb |
0.6 mmol/l calcium |
1.6 mmol/l calcium |
|
|
||||
|
T-47D |
+ |
Blastic |
35c |
2 |
|
ZR-75-1 |
+ |
Lytic |
50 |
15 |
|
MCF-7 |
+ |
Blastic |
80 |
10 |
|
Hs-578T |
- |
Blastic |
100 |
10 |
|
BT-549 |
- |
Lytic |
150 |
10 |
|
MDA-MB-231 |
- |
Lytic |
150 |
60 |
|
|
||||
|
aAs described by American Type Culture Collection (Manassas, VA, USA). bAs defined by Yin and coworkers [32] and Lacroix and colleagues [33]. cHalf maximal inhibitory concentration (IC50) values determined from concentration-effect curves for cancer cells exposed for 72 hours to ibandronate (1 to 1,000 μmol/l) in the presence of 0.6 or 1.6 mmol/l calcium. Cell culture densities were evaluated by crystal violet staining assay. Means of results pooled from three experiments (n = 18). ER, oestrogen receptor. |
||||
|
Journé et al. Breast Cancer Research 2008 10:R4 doi:10.1186/bcr1845 |
||||